All right, we're going to kick it off. I'm Tycho Peterson from the Life Science team. It's my pleasure to introduce Natera. Welcome, Mike.
Hey. Good to be here.
Been a busy couple weeks for you.
Yeah.
Why don't we maybe just kick it off with just a quick state of the union, how you're feeling coming out of the quarter? You obviously have a CEO transition. Maybe kind of talk to both those dynamics.
Yeah, had a fantastic quarter, another record quarter for Signatera growth in particular. Really strong kind of organic gross margin performance in the quarter. I was quite pleased with that. Continued progress on ASPs really across the board, but Signatera in particular, we had another sequential growth quarter in ASPs. Year-on-year, we grew revenues 42% ex-true-ups. I think for us to be at this scale now where we completely reset our guide for the year on the Q3 call, where we are now, the full range is now north of $3 billion in revenues for the year. To still be growing at 40% plus ex-true-ups at a $3 billion dollar scale, I think that gives you some sense of the size of the market that we are penetrating now with Signatera.
It is probably about a $20 billion dollar revenue annual opportunity, and we are just maybe $1 billion into it today. All of the effort really reflects where we are in terms of that evolution. Absolutely hair on fire with important clinical trials, large prospective readouts we have had this year and that we have scheduled for next year. In addition to the base business ramping the way it is, I am very excited about being able to read out the FIND-CRC study next year, which will be an outcomes trial in early cancer detection for colorectal cancer, which has the potential to be the anchor that doubles the addressable market that we are pointed at here in the relative near term. So, really excited all around. We announced a CEO transition, which maybe a few of you have heard about.
After eight years in the role as CEO and 16 years at the company, Steve is stepping away, and Solomon Moshkevich, who has been here a similar amount of time, is stepping into the role. Steve's departure, I think, is just normal course. He has had a fantastic run, was looking forward to taking a break after leading the company through a lot of discontinuous change and a lot of success and growth. As we mentioned on the call, Steve actually hired Solomon when there were about 40 people in the business. Steve and Solomon shared an office, a tiny little office, and I have seen this office, it truly is undistinguished and small, that they shared for a couple years just calling on accounts. Solomon was initially hired as a sales rep after having been a consultant at Bain and completing business school at Stanford.
He really had a lot of conviction in molecular diagnostics as a space and Natera in particular, so took a job as an entry-level sales rep working for Steve.
He has since worked across the business, across the enterprise, from running marketing for women's health to being a co-inventor of the Prospera test, our liver transplant rejection monitoring test, to being really one of the original authors of Signatera as a product, the original general manager for oncology in the business, and is really probably the person that is singularly most responsible for the evolution of Signatera from what it was at the beginning, which was me, Steve, and Solomon trying to convince people that this is going to work, that we could actually have a personalized blood test that you can scale and that would have a lot of clinical utility, to now it is quite heartening to come to conferences like the Jefferies Conference and minimal residual disease and recurrence monitoring is its own industry vertical.
A lot of success and progress that Solomon has largely been responsible for.
It is just a natural evolution in our leadership team for him to now take the role as CEO. A lot of continuity there. One thing that is a little bit unique about Natera is how long tenured the broader management team is. I am talking about several of the board members are co-founders. Our Chairman is a co-founder. Matt Rabinowitz, who has hired kind of each one of us on the management team over the last decade. I am still the newcomer to the team, and I have been here 11 years. So that gives you some sense of the long duration of the team that we have had here.
And what that means is that we have gone through a lot together, we have learned a lot together, and we are all really close friends. This was a really friendly transition between Steve and Solomon, and I think Solomon is really positioned for great success.
We still have Steve available to us. It is a warm handoff. I was just texting with him before coming up on stage on just random esoteric details. So it is a good warm transition between Steve and Solomon, and I think we are well set up for 2027.
I think in terms of the other thing that came out in the quarter you obviously put out a revenue target, $6 billion by 2029. Just talk a little bit about, or $6 billion plus, talk about the thought process behind that and maybe the bridge to get there. What are some of the big pieces we should be thinking about?
Yeah, I think there are a couple of rationales for putting out the target. One was obviously, given the transition of the leader of the company, that can be cause for concern, completely understandably among investors. What we wanted to do in part was just to reassure external parties, partners, and investors, and other stakeholders that everything's still going great. I mean, we are absolutely on an amazing roll at Natera, and we thought that putting out a longer-range target would provide some additional visibility into the business, and frankly, just inspire more folks to just put pen to paper and just understand, well, how challenging would it be to go from $3 billion in revenues roughly in 2026 and get to $6 billion in revenues by 2029. I hope that when people do that math, the execution required to double the revenues, it would require good execution.
It's going to require good performance from the team, and it should be viewed as a goal that we're going to work hard to get to. But it's also not a dream. It's not some wildly unrealistic scenario. Basically, what it requires from us is to continue execution in the core business. What that implies is just modest but continued growth in the women's health business. Same answer for the transplant, the organ health business. In Signatera, I think on the volume side, I think it just requires us to continue to kind of hit our marks as it relates to new patient growth, roughly equivalent with continuing to do what we've done as a target, which is to kind of grow consonant with the rolling four quarters average of quarterly unit growth.
On the ASP front, you can get to $6 billion, obviously, at a range of ASPs, but what we said on the call is $1,450, we think is a reasonable target for that time horizon, and you could well exceed that. The same spirit should apply, though. I think given our ASPs right now for Signatera are about $1,290- $1,450 should strike you as, hey, that's a goal that's going to require some good execution. A lot of good things need to go well, a lot of clinical trials need to read out positively, and yet it's not pie in the sky. It's not something that is unrealistic. It's eminently achievable if we continue to hit our marks.
That $160 bridge between where you are today, where you could end up, can you maybe just give us-
Sure
some breakdown between MolDX, tumor type coverage, commercial payer, Medicare Advantage, how you think about those pieces?
Well, we've talked about in the past that we've got nine now, Signatera MolDX coverage applications in flight with the MolDX program. We were very pleased to get covered for liver cancer just before the Q3 earnings call, and we've got a bunch of very similar dossiers before those committees now over at MolDX. We've mentioned in the past that the benefit to ASPs just by getting covered in a broader set of tumor types by Medicare and Medicare Advantage payers could be worth something like $200-$300 in ASP. So, if you just held steady on the rest of the variables in the Signatera ASP and you got all of those MolDX coverage decisions, that would bridge you by itself. Of course, there's other things that we're working on in parallel.
We've got the continued execution that we'd like to deliver in just driving compliance on this long tail of Medicare Advantage payers, making sure that they reimburse us for Medicare coverage services related to Signatera. Of course, we've got the potential to get broader reimbursement for commercial patients in the biomarker states. So, these are commercial insured patients that live in a state in the U.S. where there's a state law on the books that says, "Hey, if you want to offer commercial health insurance in my state, you've got to offer the same level of care that Medicare offers." Driving compliance with that standard is something that really ends up looking like an execution challenge for us, and we've made steady progress on that over time.
I think just with those, I think you've got a number of different ways to kind of reach this target. I haven't really mentioned anything about getting into clinical practice guidelines. I think over that time horizon, I think that should be a possibility. May not happen, but I think it's something that, just given the depth and breadth of evidence we have in colorectal cancer and breast cancer, I would certainly like to be in consideration for broader adoption in the NCCN guidelines in slices of both of those tumor types over the next three years.
On the volume side, how should we think about new patient starts versus surveillance protocol?
Yeah. So, I mean, one of the things that is I know many of you have your own Signatera kind of volume forecasts, and it ends up working like a waterfall, where because this is a repeat monitoring test for patients, you are really trying to get an understanding of how many tests will a patient get, how many Signatera tests will a patient get over the course of their journey, over the course of a five-year journey? And then secondarily, as Tycho Peterson mentioned, how many new patients can you start every quarter? So, very rough justice, in a given quarter, something like 10%-15% of the total clinical MRD volumes that we deliver in a quarter will represent new patient starts. And sometimes it is 15%, and sometimes it is 10%. There is a lot of just kind of randomness and variability quarter to quarter in that number.
I will tell you, as we mentioned on the call just a few weeks ago, the recent new patient starts look incredibly strong. Okay? So, I feel like the new patient starts just continue to be on an an upward trajectory, which bodes very well for the future. Why is that? Because we have a very good understanding with how commonly people stay with Signatera over the course of their five-year journey. That is a very well-understood kind of attrition curve over time, and the compliance is extremely high because of the clinical utility that each of these tests deliver over time, both in terms of steering treatment within a patient's adjuvant treatment journey and then monitoring for recurrence once they are in remission.
So, in terms of the assumptions, there is really nothing heroic in the assumptions around changing the number of tests per patient that a patient gets over their journey.
No discontinuous change there. No change in the rate at which existing Signatera patients actually stay with us over time. So, that attrition curve remains the same. Then it is just a matter of just modeling what we think would represent good execution, but not heroic execution, in terms of adding additional patients, roughly in line with the history that we have demonstrated there.
How should we think about MolDX phasing? You mentioned the dossiers and new indications. I think in the past, you've talked about $250 million-$300 million from the seven new indications.
Yeah.
How do you think about that turning into coverage decisions and then ultimately paid volume?
Yeah. So, I think just because there were, at the time when I was giving that answer, there were roughly like 1 million Signatera tests per year. So it just happened to work out that the $200 or $300 in ASP also kind of matched up to the $200 million and $300 million. As you grow the Signatera volumes, the revenue opportunity actually grows. When I was saying $200 - $300 previously in this chat, I was talking about the impact to ASP compared to this $1,450 ASP that we had laid out as a 2029 target. Just to clarify those couple numbers. So, the path there is really well established. This is year seven of us making submissions to the MolDX program. Well established, what you need to submit in terms of a pretty rigorous set of analytic and clinical validity studies to the committee.
It usually takes them nine to 12 months to turn back a finalized response. We're kind of tracking in that time zone today.
Then maybe just touch on Signatera Genome, the roadmap here, and where is the test resonating? It is still obviously kind of early days. How do you think about the opportunity on Signatera Genome?
Yeah, it is a massive opportunity. I think just for further context, the majority of patients today in the clinical setting receive a Signatera test that is designed on an exome backbone. An exome is just the 20,000 genes in the genome that we know code for proteins. That assay has performed extremely well and continues to read out prospective outcome studies that are extremely positive. We have long held the opinion inside the company that our core strategy has got to be continuously obsoleting ourselves. We have got to always be thinking about what is next, how do we improve the Signatera assay even beyond the excellent performance it has already shown. The way that we see to do that is by doing two things. One is by expanding the baseline setup test from just the exome to a whole genome. So now you are sequencing the entire genome.
You get a broader menu of variants to select from when designing this personalized Signatera assay for each patient. So we will broaden the number of targets that we track for each individual patient based on this broader set, broader menu that we get from having run the genome. Then we are going to layer on one additional technology called phased and/or structural variants. The idea behind phased and structural variants is that as you are running these repeat plasma tests for patients, you will get a ping on one or more of these variants that you are trying to track. But the ping, the fluorescence from the sequencer will be so faint that it is actually below the error threshold of the instrument.
So absent any other information, you are obviously reluctant to call that patient as positive, as likely to have a clinical relapse, because the fluorescence that you saw, the notification from the sequencer that you saw, is actually below its own error profile. It is below the noise profile that you could get random noise from the sequencer. But if you can string a couple of those targets together, even if each individual signal is quite faint, the phase of three of these together makes it extremely unlikely that you would get three of those notes in the song strung together, even though they are individually, they are all below the error profile of the sequencer. So that allows us to go much deeper in terms of our sensitivity that we can deliver to patients without yielding meaningful additional false positives.
That's the plan, and that's what has borne out so far in the clinical trial data that we've been able to present so far on Signatera Genome. Over the next year and a half, the data that will be available to you in the clinical setting for the Signatera Genome backbone with phased variants is going to expand dramatically. We've got a number of very long-dated prospective outcomes trials that we've been running for years that will read out in 2027 and in 2028, where we will dutifully read out what the results were on the original Signatera test. In each of those studies, we have pre-specified protocols to take an additional tube of blood, additional sample, so that at the same time, we can read out to you what the results would be on the latest and greatest Signatera test.
I think that is going to be something that ends up causing some acceleration in the demand for Signatera Genome, and it's another way where we can really accelerate our ability to have fully validated latest and greatest technology with the backing of long-dated outcomes trials, because we've got this infrastructure of these clinical trials that are already in flight. I think that's going to drive some demand. Over time, the net effect of that is that we're going to just continue to deliver a best-in-class offering for patients. Interestingly, the COGS at the moment for the Signatera Genome backbone version of the test is a bit higher than what we experience right now for the exome, which has now had years for us to get the COGS optimized. We will do that again.
We will go through that journey again on the Signatera Genome product. To the extent there are kind of bubble costs associated with COGS, I expect those to be relatively temporary, kind of on the scale of a couple of quarters. In return for that, you've got the best quality test that will be in place for a long time.
Is that inclusive of a phase variant cost?
Yeah. The phased variants do not actually add a lot of cost because you are really, it is an addition to the algorithm that you are running.
Okay. Early cancer, big market, early days.
Yep.
You have obviously got a fair number of competitors coming into the market. What is the sensitivity specificity threshold you need to come to market with, and what is kind of your right to win in early cancer?
Yeah, it is a good question. I think everyone in the room is entitled to their own opinion on that question. My own take has evolved on ECD quite a bit, just in the spring. Originally, I think embarking on a program to have an early cancer detection program struck me as quite a risky bet when we embarked on this journey three or four years ago. The challenges are vast. You have got to spend something like $400 million-$500 million before you get to sell a single test in this market. So, it is an enormous technical challenge to conceive and deliver a blood test that performs with sufficient accuracy to be used in an early cancer detection population. Then you have got to run a massive clinical trial.
I mean, the FIND-CRC study is going to be 25,000+ prospectively enrolled patients that we will then read out next year. It is an absolute massive investment over the course of many years. You have to launch that journey before you even know what the commercial reimbursement landscape is going to look like. But just this spring, we can see now that, as we had hoped, commercial payers are actually quite constructive in terms of being willing to cover an early cancer detection test, specifically for colorectal cancer. That is a huge relief to your humble bean counter here, that the math is actually going to pencil out after having already made this investment. In terms of the performance that we need, look, we will just have to see.
I mean, there is a reason why you have to read out the big study, because the smaller studies that we have read out to date are not powered to give you the definitive answer that we will take before the FDA. My general take is that if we are in line with the other players that are already on the market, I will stipulate that the other players that are on the market, and there is really two of them, these are both excellent companies with excellent track records of excellent commercial execution, but we are pretty good too. We have a decent track record of commercial execution around here, and I think that we will be able to take our fair share. What is our fair share?
I will just remind you, part of the reason why the payers are eager to reimburse this test is that there are 40 million Americans that need a colorectal cancer screen and are not going to avail themselves of a colonoscopy or a fecal stool test. They are just not going to comply with the form factor required in each of those two diagnostic settings, so they will get nothing, absent a blood test. But if you offer a high-quality blood test, that makes a huge difference in terms of the health economics for the system, and it makes a huge difference for these individual patients. My theory would be that you need one of these blood tests once every three years. It is possible that could become more frequent over time, but initially, you get one of these tests once every three years.
That means there are 13 million-14 million people a year that would hugely benefit from getting one of these blood tests for colorectal cancer screening. You need not make heroic market share assumptions for us to see how we could go from zero tests right now, $100 million-$150 million in spend on the R&D line, so it is just an absolute boat anchor on our P&L right now that harms us, to something that goes from zero tests to millions of tests per year over the three- or four-year time horizon once we have launched the test. I am very excited about that. Following on from colorectal cancer, there are a number of populations that have an elevated risk for cancer occurrence.
Given that if we can get an assay to work in the colorectal cancer setting, the bar is actually, I would argue, because the incidence rate of cancer is higher, it is more straightforward for me to understand how we will be able to design and execute prospective clinical trials that will show enormous benefit in additional high-risk populations. Even a conservative accounting of these high-risk populations, inclusive of colorectal cancer, if you sum those populations up, you are talking about a population that is about the same size as the available population for Signatera.
Now that we see that the reimbursement landscape is going to be constructive, I can now have really clear line of sight, I think, to having a market in Signatera, which will really just be hitting its stride in 2029 and 2030, and then doubling the addressable market, doubling the volume of patients and testing we can serve in a given year at the same time. I am very excited about that future evolution of the company.
I know we are close to the end. I just want to make sure we hit on pharma because it is an important and growing part of the business. You have got trial services, companion diagnostics, data licensing. Maybe just talk a little bit about how you are thinking about pharma.
Well, so the floodgates really opened for us on pharma when we read out the IMvigor trial, roughly this time last year. We ran a prospective clinical trial with Roche using atezolizumab in muscle-invasive bladder cancer, where Roche had run an initial phase III trial, all comers with atezo, that did not meet its primary endpoint. We quickly re-ran a second phase III clinical trial in which Signatera was used as entrance criteria for that study, meaning Signatera-positive patients were then randomized plus or minus atezolizumab. We went from a drug that did not meet its primary endpoint to a drug that had like a 40% treatment effect. So, massive seminal result in the field of cancer care was published in the New England Journal of Medicine.
Interestingly, for the pharma company, you went from an indication that was not going to be approved to now an indication that is approved for atezo, and they were able to run that clinical trial in about half the time and a fraction of the cost of a traditional phase III clinical trial. So, after that result, what had already been an interesting area of exploration for pharma has really quickened quite a bit. We've had a massive increase in just our total contracted value and just the number of large and strategic clinical trials in which we're partnering with pharma. I'm very excited about what that means. The pharma business is one thing in terms of its own revenue contribution, but what is really important to me is the impact we can have with patients when these prospective clinical trials read out.
Awesome. We're at time. We'll leave it at that. Thanks.
Awesome. Thank you so much.